Drug Interaction "Risk Level" Categories May Be Developed By FDA
Executive Summary
FDA is considering assigning "risk levels" to drug-drug interactions to better communicate the clinical significance in labeling, FDA Office of Clinical Pharmacology & Biopharmaceutics Science and Regulatory Policy Associate Director Shiew-Mei Huang told a recent meeting of the American Association of Pharmaceutical Scientists.